Drug intelligence / Profile preview

Prof-005

Development stage: Preclinical
Lead developer: ProFem

Overview

Prof-005 is a preclinical-stage drug candidate being developed by ProFem, an Austrian biotechnology company focused on women's health. The agent is currently being investigated for the treatment of overactive bladder (OAB) and urge urinary incontinence (UUI). As of the current pipeline status, Prof-005 is identified as a lead candidate in the preclinical phase. While ProFem's lead programs often focus on biofilm resistance and microorganism-host interactions, specific details regarding the molecular modality, biological targets, and exact mechanism of action for Prof-005 have not yet been publicly disclosed.

Beyond the preview

Go deeper on Prof-005.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Prof-005.

Explore the full profile